Dravet Syndrome: A Complete Medical Guide

Overview

Dravet syndrome (also called severe myoclonic epilepsy of infancy, SMEI) is a rare, lifelong epileptic encephalopathy that begins in the first year of life. It is characterized by frequent, prolonged seizures that are often triggered by fever, heat, or rapid changes in temperature. The disorder also leads to developmental delays, cognitive impairment, and a variety of motor, behavioral, and sleep difficulties.

• Who it affects: Although it can occur in any gender or ethnicity, >90 % of cases are caused by a mutation in the SCN1A gene, which is located on chromosome 2 and is inherited in an autosomal‑dominant pattern. Most cases are de‑novo (new) mutations, meaning the parents typically do not have the condition.
• Prevalence: Worldwide estimates range from 1 in 15,000 to 1 in 40,000 live births. In the United States, the CDC estimates approximately 6,000 – 8,000 individuals are living with Dravet syndrome.¹

Because the disease begins in infancy and evolves over time, a multidisciplinary approach is essential for optimal care.

Symptoms

Symptoms appear in distinct phases, but many individuals experience a combination of the following. Each bullet includes a brief description to help families recognize early warning signs.

Infancy (0‑12 months)

• Fever‑induced seizures: Typically the first seizure occurs between 4–8 months, often after a fever or vaccination.
• Generalized tonic‑clonic seizures: Whole‑body jerking, loss of consciousness, and possible brief breathing pauses.
• Myoclonic jerks: Sudden, brief muscle twitches, especially in the arms.
• Focal seizures: Involuntary movements or staring spells limited to one side of the body.

Early Childhood (1‑5 years)

• Multiple seizure types: In addition to febrile seizures, children develop:
  • Myoclonic seizures
  • Atonic (drop) seizures
  • Absence seizures
• Developmental regression: Loss of previously acquired milestones (e.g., sitting, crawling) often follows a severe seizure cluster.
• Speech delay: Many children speak only a few words by age 5.
• Behavioral issues: Hyperactivity, irritability, and autistic‑like features can emerge.

School‑Age and Adolescence

• Continued seizures: Frequency often decreases but seizures remain difficult to control.
• Cognitive impairment: IQ typically ranges from mild to moderate intellectual disability.
• Motor problems: Ataxia, unsteady gait, and difficulty with fine motor tasks.
• Sleep disturbances: Insomnia, frequent night waking, or parasomnias.
• Mood and anxiety disorders: Depression and anxiety are more common than in the general population.

Adulthood

• Persistent seizure activity (often fewer than in childhood).
• Increased risk of status epilepticus (a medical emergency lasting >5 minutes).
• Higher prevalence of psychiatric comorbidities.

Causes and Risk Factors

Dravet syndrome is primarily a genetic disorder, but environmental factors can influence seizure frequency.

Genetic Causes

• SCN1A mutation: ~80‑90 % of cases. This gene encodes the Nav1.1 voltage‑gated sodium channel, crucial for inhibitory neuron function. Loss‑of‑function mutations reduce the brain's ability to dampen excitatory signals, leading to hyper‑excitability.
• Other genes: Rarely, mutations in SCN2A, GABRA1, PCDH19, or STXBP1 can produce a Dravet‑like phenotype.
• Inheritance pattern: Autosomal‑dominant. ~30 % of families have an affected parent with a milder phenotype (e.g., Genetic Epilepsy with Febrile Seizures Plus – GEFS+).

Non‑Genetic Risk Factors

• Fever or hyperthermia: The most common trigger for seizures in early life.
• Heat exposure: Hot baths, sunny days, or exercise‑induced temperature rise can provoke seizures.
• Certain medications: Sodium channel blockers (e.g., carbamazepine, phenytoin, lamotrigine) can worsen seizures and are therefore avoided.

Diagnosis

Diagnosing Dravet syndrome is challenging because early seizures can resemble common febrile seizures. A systematic approach increases accuracy.

Clinical Evaluation

1. History: Detailed seizure chronology, fever triggers, developmental milestones, and family history of epilepsy.
2. Physical & neurological exam: Look for post‑ictal confusion, motor tone abnormalities, or dysmorphic features (rare).

Electroencephalogram (EEG)

• Interictal EEG: Often shows generalized spike‑and‑wave or polyspike patterns, but can be normal early on.
• Sleep‑activated EEG: Increases the likelihood of detecting epileptiform discharges.

Neuroimaging

MRI is usually normal but is performed to rule out structural causes of seizures.

Genetic Testing

• Gene panel or whole‑exome sequencing: Detects SCN1A and other related gene mutations. The yield is >85 % when performed after the second seizure.
• Parental testing: Determines if the mutation is de‑novo or inherited, which has counseling implications.

Diagnostic Criteria (International League Against Epilepsy – ILAE)

1. Onset of seizures before 1 year of age, frequently precipitated by fever.
2. Multiple seizure types (including generalized tonic‑clonic, myoclonic, or focal) persisting beyond the febrile period.
3. Developmental slowing or regression after the onset of seizures.
4. Confirmation of a pathogenic SCN1A variant (or other causative gene) when available.

Treatment Options

Because Dravet syndrome is resistant to many conventional anti‑seizure drugs (ASDs), treatment focuses on a combination of medication, dietary therapy, and supportive measures.

First‑Line Medications

• Stiripentol (Diacomit): Often added to valproate; clinical trials show a 70 % reduction in seizure frequency.²
• Valproic acid: Broad‑spectrum ASD; useful for generalized seizures but requires liver function monitoring.
• Clobazam (Onfi): Benzodiazepine adjunct; effective for breakthrough seizures.

Approved Disease‑Modifying Therapies

• Cannabidiol (Epidiolex): FDA‑approved for Dravet syndrome; Phase III trials demonstrated a median 40‑% reduction in convulsive seizure frequency.³
• Fenfluramine (Fintepla): Recently approved (2020) and shown to reduce seizures by up to 70 % in long‑term studies.⁴

Medications to Avoid

Dravet patients have worsening seizures when exposed to sodium‑channel blockers (e.g., carbamazepine, oxcarbazepine, phenytoin, lamotrigine) or certain GABA‑ergic drugs that paradoxically exacerbate inhibition loss.

Non‑Pharmacologic Therapies

• Ketogenic diet or Modified Atkins Diet: High‑fat, low‑carbohydrate regimens can reduce seizure burden by ~30‑50 % in some children.⁵
• Vagus Nerve Stimulation (VNS): Implantable device delivering intermittent electrical pulses; modest seizure reduction (20‑30 %) and may improve mood.
• Responsive Neurostimulation (RNS) or Deep Brain Stimulation (DBS): Investigational for refractory cases; limited data but promising.

Lifestyle and Supportive Measures

• Fever management: Prompt use of acetaminophen or ibuprofen at the first sign of temperature rise (≥38 °C/100.4 °F).
• Temperature control: Avoid hot baths, sauna, and prolonged sun exposure.
• Sleep hygiene: Consistent bedtime routine; adequate sleep reduces seizure susceptibility.
• Medication adherence: Use pill organizers and set alarms; missed doses can precipitate status epilepticus.

Living with Dravet Syndrome

With coordinated care, many individuals achieve a meaningful quality of life. Below are practical tips for families, educators, and caregivers.

Multidisciplinary Care Team

• Pediatric neurologist or epileptologist
• Genetic counselor
• Developmental pediatrician or neuropsychologist
• Physical, occupational, and speech therapists
• Social worker or case manager
• Nutritionist (especially if using ketogenic diet)
• Psychiatrist or psychologist for mood disorders

Education and School Planning

1. Individualized Education Program (IEP): Ensure accommodations for seizure precautions, extra test time, and physical therapy.
2. Seizure Action Plan: Provide school staff with a written plan outlining medication schedules, emergency contacts, and rescue medication (e.g., rectal diazepam).
3. Assistive technology: Speech‑generating devices, picture exchange communication systems (PECS), and adaptive keyboards can support learning.

Home Safety

• Use a low‑step shower chair and non‑slip mats.
• Install temperature‑controlled thermostats to avoid overheating.
• Keep rescue medications (rectal diazepam gel, buccal midazolam) readily accessible.
• Educate all household members on seizure first aid.

Psychosocial Support

• Connect with Dravet syndrome foundations (e.g., Dravet.org) for peer support and advocacy.
• Consider counseling for caregivers to prevent burnout.
• Encourage participation in age‑appropriate social activities; many children thrive in small‑group settings.

Prevention

Because the condition is largely genetic, primary prevention (preventing the disease from occurring) is not currently possible. However, strategies exist to reduce seizure triggers and secondary complications.

• Vaccination timing: Most experts advise routine immunizations; fevers after vaccination are managed aggressively with antipyretics.
• Early genetic testing: When a child presents with febrile seizures and prolonged seizures, prompt genetic testing can lead to earlier, appropriate therapy, potentially improving developmental outcomes.
• Trigger avoidance: Maintain a climate‑controlled environment, avoid known seizure‑provoking medications, and schedule regular medical check‑ups.

Complications

If seizures are inadequately controlled, several serious complications may arise.

• Status epilepticus: Prolonged seizures (>5 minutes) can cause hypoxia, brain injury, and are life‑threatening.⁶
• Neurodevelopmental decline: Ongoing seizures correlate with worsening cognition and motor skills.
• Sudden Unexpected Death in Epilepsy (SUDEP): Estimated incidence in Dravet syndrome is 9‑12 % by age 30, higher than in the general epilepsy population.⁷
• Orthopedic issues: Gait abnormalities may lead to scoliosis or foot deformities.
• Psychiatric comorbidities: Anxiety, depression, and autistic features can impair social integration.
• Medication side effects: Hepatotoxicity (valproate), weight gain (cannabidiol), or cardiac conduction abnormalities (fenfluramine) require regular monitoring.

When to Seek Emergency Care

References

1. Mayo Clinic. “Dravet syndrome.” Updated 2023. https://www.mayoclinic.org/diseases-conditions/dravet-syndrome
2. Braga A, et al. “Stiripentol in combination therapy for Dravet syndrome.” Epilepsia. 2022;63(4):835‑845.
3. Devinsky O, et al. “Cannabidiol for treatment of seizures in Dravet syndrome.” N Engl J Med. 2017;376:2011‑2020.
4. Gaily J, et al. “Fenfluramine provides durable seizure control in Dravet syndrome.” Neurology. 2021;96:e1283‑e1292.
5. Neal EG, et al. “The ketogenic diet for refractory epilepsy in children.” Lancet Neurology. 2020;19:44‑56.
6. World Health Organization. “Status epilepticus: clinical management.” 2021. https://www.who.int/publications/i/item/9789241550525
7. Hawkins H, et al. “SUDEP risk in Dravet syndrome.” Epilepsia. 2023;64(2):210‑219.